Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Navarro-Compán V, Gensler L, Rudwaleit M, Ganz F, Chen S, Stigler J, Schmagel A, Baraliakos X (2023)
In: ACR Convergence 2023 Abstract Supplement. Arthritis & Rheumatology , 75(Suppl. 9). Hoboken: Wiley: 2739-2741.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Navarro-Compán, Victoria;
Gensler, Lianne;
Rudwaleit, MartinUniBi;
Ganz, Fabiana;
Chen, Shirley;
Stigler, Jayne;
Schmagel, Anna;
Baraliakos, Xenofon
Einrichtung
Erscheinungsjahr
2023
Titel des Konferenzbandes
ACR Convergence 2023 Abstract Supplement
Serien- oder Zeitschriftentitel
Arthritis & Rheumatology
Band
75
Ausgabe
Suppl. 9
Seite(n)
2739-2741
Konferenz
ACR Convergence 2023
Konferenzort
San Diego, CA
Konferenzdatum
2023-11-10 – 2023-11-15
ISSN
2326-5191
eISSN
2326-5205
Page URI
https://pub.uni-bielefeld.de/record/2993450
Zitieren
Navarro-Compán V, Gensler L, Rudwaleit M, et al. Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials. In: ACR Convergence 2023 Abstract Supplement. Arthritis & Rheumatology . Vol 75. Hoboken: Wiley; 2023: 2739-2741.
Navarro-Compán, V., Gensler, L., Rudwaleit, M., Ganz, F., Chen, S., Stigler, J., Schmagel, A., et al. (2023). Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials. ACR Convergence 2023 Abstract Supplement, Arthritis & Rheumatology , 75, 2739-2741. Hoboken: Wiley. https://doi.org/10.1002/art.42700
Navarro-Compán, Victoria, Gensler, Lianne, Rudwaleit, Martin, Ganz, Fabiana, Chen, Shirley, Stigler, Jayne, Schmagel, Anna, and Baraliakos, Xenofon. 2023. “Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials”. In ACR Convergence 2023 Abstract Supplement, 75:2739-2741. Arthritis & Rheumatology . Hoboken: Wiley.
Navarro-Compán, V., Gensler, L., Rudwaleit, M., Ganz, F., Chen, S., Stigler, J., Schmagel, A., and Baraliakos, X. (2023). “Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials” in ACR Convergence 2023 Abstract Supplement Arthritis & Rheumatology , vol. 75, (Hoboken: Wiley), 2739-2741.
Navarro-Compán, V., et al., 2023. Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials. In ACR Convergence 2023 Abstract Supplement. Arthritis & Rheumatology . no.75 Hoboken: Wiley, pp. 2739-2741.
V. Navarro-Compán, et al., “Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials”, ACR Convergence 2023 Abstract Supplement, Arthritis & Rheumatology , vol. 75, Hoboken: Wiley, 2023, pp.2739-2741.
Navarro-Compán, V., Gensler, L., Rudwaleit, M., Ganz, F., Chen, S., Stigler, J., Schmagel, A., Baraliakos, X.: Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials. ACR Convergence 2023 Abstract Supplement. Arthritis & Rheumatology . 75, p. 2739-2741. Wiley, Hoboken (2023).
Navarro-Compán, Victoria, Gensler, Lianne, Rudwaleit, Martin, Ganz, Fabiana, Chen, Shirley, Stigler, Jayne, Schmagel, Anna, and Baraliakos, Xenofon. “Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials”. ACR Convergence 2023 Abstract Supplement. Hoboken: Wiley, 2023.Vol. 75. Arthritis & Rheumatology . 2739-2741.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar